Enzinger and Weiss's Soft Tissue Tumors: A Comprehensive Guide to Diagnosis and Treatment
Soft tissue tumors are a diverse group of neoplasms that arise from connective tissue, fat, muscle, nerve, blood vessels, and other supporting tissues of the body. They can be benign or malignant, and they can affect people of any age and location. Some of the most common types of soft tissue tumors include lipomas, leiomyomas, schwannomas, hemangiomas, and sarcomas.
Enzinger and Weiss's Soft Tissue Tumors is a classic reference book that provides comprehensive and authoritative information on the diagnosis and treatment of these challenging lesions. The book covers the histopathology, immunohistochemistry, molecular genetics, clinical features, differential diagnosis, prognosis, and management of more than 200 types of soft tissue tumors. It also includes numerous illustrations, tables, algorithms, and case studies to aid in the recognition and classification of these tumors.
The book is now in its seventh edition[^1^], which has been extensively revised and updated to reflect the latest advances and discoveries in the field. The new edition features new chapters on molecular pathology, immunotherapy, targeted therapy, and rare tumors; expanded coverage of pediatric tumors, vascular tumors, and soft tissue infections; updated WHO classification and grading systems; and more than 2000 new color images.
Enzinger and Weiss's Soft Tissue Tumors is an indispensable resource for pathologists, oncologists, surgeons, radiologists, and other clinicians who encounter soft tissue tumors in their practice. It is also a valuable reference for students, residents, fellows, and researchers who want to learn more about this fascinating and evolving area of medicine.
If you are interested in reading this book, you can download a free PDF version from the link below[^2^]. However, please note that this is an unofficial copy that may not be complete or accurate. We recommend that you purchase the original book from a reputable publisher or online store for the best quality and reliability.Soft tissue tumors are relatively rare compared with other types of cancers. According to the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, the estimated number of new cases of soft tissue cancer in the United States in 2022 is 13,190, which accounts for 0.7% of all new cancer cases. The estimated number of deaths from soft tissue cancer in 2022 is 5,130, which accounts for 0.8% of all cancer deaths. The five-year relative survival rate for soft tissue cancer is 65.4%, which varies depending on the stage and type of tumor[^3^].
Soft tissue tumors can occur in any part of the body, but some sites are more common than others. The most frequent locations are the extremities (41%), trunk (19%), retroperitoneum (15%), head and neck (10%), and thorax (9%). The incidence of soft tissue tumors also varies by age and sex. Soft tissue tumors are more common in men than in women, with a male-to-female ratio of 1.2:1. The median age at diagnosis is 57 years for men and 54 years for women. However, some types of soft tissue tumors have a different age distribution. For example, rhabdomyosarcoma is the most common soft tissue sarcoma in children and adolescents, whereas liposarcoma and leiomyosarcoma are more common in older adults.
The classification and staging of soft tissue tumors are based on histologic features, immunohistochemical markers, molecular genetics, and clinical behavior. The World Health Organization (WHO) has published a series of updates on the classification of soft tissue tumors, which recognizes more than 200 entities and subtypes. The WHO classification groups soft tissue tumors according to their presumed cell of origin or differentiation, such as adipocytic, fibroblastic/myofibroblastic, smooth muscle, skeletal muscle, vascular, perivascular, neural/neuroendocrine/neuroectodermal, chondro-osseous, synovial-like mesenchymal cells, uncertain differentiation, etc.
The staging of soft tissue tumors is based on the tumor size, depth, grade, nodal status, and metastasis. The most widely used staging system is the American Joint Committee on Cancer (AJCC) TNM system, which assigns a stage from I to IV based on the following criteria:
T: primary tumor size and depth (T1: â 5 cm and superficial; T2: â 5 cm and deep or > 5 cm; T3: > 5 cm)